Increasing bowel cancer testing rates through a general practitioner-organised health care package would reduce incidence and prove cost-effective
Treating bowel cancer is expensive, and the cost is rising rapidly. In the past decade, costs have increased for treating cancers at all stages (in particular, Stages 3 and 4), largely due to increased chemotherapy options and the introduction of more effective but expensive drug regimens.1 Increased treatment costs are a stimulus for the considerable effort in the areas of prevention and early detection.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. O’Leary B, Olynyk J, Neville M, Platell C. Cost effectiveness of colorectal cancer screening: comparison of community-based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy. J Gastroenterol Hepatol 2004; 19: 38-47.
- 2. Cenin DR, St John DJ, Ledger MJ, et al. Optimising the expansion of the National Bowel Cancer Screening Program. Med J Aust 2014; 201: 456-461. <MJA full text>
- 3. KPMG. Review of the National Bowel Cancer Screening Program (Phase 2): Final report, part one. Canberra: Department of Health and Ageing, 2012. http://cancerscreening.gov.au/internet/screening/publishing.nsf/Content/C1EED399C650C2F3CA257D8D001F10E9/$File/review-nbcsp-fr-p1.pdf (accessed Apr 2015).
- 4. Australian Institute of Health and Welfare. Australian cancer incidence and mortality book for colorectal cancer. Canberra: AIHW, 2015.
- 5. Young JP, Win AK, Rosty C, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol 2015; 30: 6-13.
- 6. Australian Bureau of Statistics. Household income and income distribution, Australia, 2011-12. Canberra: ABS, 2013. (ABS Cat. No. 6523.0.) http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/6523.02011-12?OpenDocument (accessed Apr 2015).
- 7. Deloitte Access Economics. Cost-effectiveness of screening for bowel cancer. Canberra: The Gut Foundation, 2011. http://www2.deloitte.com/au/en/pages/economics/articles/cost-effectiveness-screening-for-bowel-cancer.html (accessed Apr 2015).
- 8. Viiala CH, Zimmerman M, Cullen DJ, Hoffman NE. Complication rates of colonoscopy in an Australian teaching hospital environment. Intern Med J 2003; 33: 355-359.
- 9. Tan-Torres Edejer T, Baltussen R, Adam T, et al, editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization, 2003. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf (accessed Apr 2015).
- 10. Bolin T, Benstock S, Fernon V, et al, editors. Further evidence to lower the recommended screening age for colorectal cancer. Paper presented at: 78th Annual Meeting of the American College of Gastroenterology; 2013 Oct 11-16; San Diego, USA. A summary of the study’s purpose, methods, results and conclusions is available at http://www.nature.com/ajg/journal/v108/n1s/pdf/ajg2013273a.pdf?WT.ec_id=AJG-201310 (accessed Aug 2015).
No relevant disclosures.